September 4, 2024

Table S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Los puntos clave no están disponibles para este artículo en este momento.

Table S4. Treatment-Emergent Adverse Events (≥3 patients) with PF-07799933 monotherapy and combination therapy

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Yaeger et al. (Wed,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar